EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans
- 1 June 2006
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 9 (6) , 421-423
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLOS Medicine, 2005
- Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProceedings of the National Academy of Sciences, 2005
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 2004
- Application of comparative functional genomics to identify best-fit mouse models to study human cancerNature Genetics, 2004
- mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathwaysNature Medicine, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Myc-driven murine prostate cancer shares molecular features with human prostate tumorsCancer Cell, 2003
- c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutationsNature Medicine, 2001